Prenatal testing revenue in the third quarter of 2025 grew 2% year-over-year, reflecting ongoing expansion of payer coverage, particularly for Foresight Expanded Carrier Screen. Prenatal volume over ...

It has been another stellar week for Genedrive after it revealed signs of commercial traction for its technology, followed by ...

Multigene next-generation sequencing (NGS) performed directly on tumor tissue can accurately identify pathogenic variants in epithelial ovarian cancer (EOC), detecting both somatic and germline ...

For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...

Ribosomes are the cell's protein factories, which read the genetic code and assemble the proteins that every organism needs ...

Scientists have successfully created immature human egg-like cells from skin-derived stem cells, a significant step in ...

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis ...

Myriad Genetics ( ($MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Standard laboratory tests can fail to detect many disease-causing DNA changes. Now, a novel 3D chromosome mapping method can ...

Bent bone dysplasia (BBD) is a perinatal-lethal skeletal disorder caused by pathogenic FGFR2 mutations that disrupt bone ...

The same cell product could potentially be used to treat multiple solid tumors like ovarian, pancreatic and lung cancers.